XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	0,059	0,070	28.04.

Realtime

Geld

Brief

Zeit

0,059

0,070

28.04.

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024

Das Instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024
The instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY is traded ex capital adjustment on 25.03.2024

Das Instrument 2XX NO0010716863 XXL ASA A NK -,40 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024
The instrument 2XX NO0010716863 XXL ASA A NK -,40 EQUITY is traded ex capital adjustment on 25.03.2024

Das Instrument 85X0 SE0016276752 BIOEXTRAX AB EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024
The instrument 85X0 SE0016276752 BIOEXTRAX AB EQUITY is traded ex capital adjustment on 25.03.2024

Das Instrument DMN SE0005162880 DIAMYD MEDICAL B EQUITY wird cum Kapitalmassnahme gehandelt am 25.03.2024 und ex Kapitalmassnahme am 26.03.2024
The instrument DMN SE0005162880 DIAMYD MEDICAL B EQUITY is traded cum capital adjustment on 25.03.2024 and ex capital adjustment on 26.03.2024

Das Instrument K26 FR001400C2Z4 ENIBLOCK EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 25.03.2024 und ex Kapitalmassnahme am 26.03.2024
The instrument K26 FR001400C2Z4 ENIBLOCK EO -,01 EQUITY is traded cum capital adjustment on 25.03.2024 and ex capital adjustment on 26.03.2024

Das Instrument RDT1 ES0172708234 GR.EZENTIS SA EO-,00013 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024
The instrument RDT1 ES0172708234 GR.EZENTIS SA EO-,00013 EQUITY is traded ex capital adjustment on 25.03.2024

Großer Insider-Report 2024 von Dr. Dennis Riedl

Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.

Hier klicken

Zeit	Aktuelle Nachrichten
15.04.	XFRA 85X0: WIEDERAUFNAHME/RESUMPTION	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen
12.04.	XFRA 85X0: AUSSETZUNG/SUSPENSION	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOEXTRAX AB 85X0... ► Artikel lesen
28.03.	Nasdaq Stockholm AB: Listing of paid subscription unit of Bioextrax AB	With effect from April 02, 2024, the paid subscription unit in Bioextrax AB will be traded on First North Growth Market. Trading will continue until further notice. Instrument: Paid subscription... ► Artikel lesen
28.03.	Nasdaq Stockholm AB: Listing of unit rights of Bioextrax AB	With effect from April 02, 2024, the unit rights in Bioextrax AB will be traded on First North Growth Market. Trading will continue up until and including April 11, 2024. Instrument: Unit rights... ► Artikel lesen
25.03.	XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024	Das Instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024 The instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY is traded ex capital adjustment on 25.03.2024Das... ► Artikel lesen

Zeit

Aktuelle Nachrichten

15.04.

XFRA 85X0: WIEDERAUFNAHME/RESUMPTION

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen

12.04.

XFRA 85X0: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOEXTRAX AB 85X0...
► Artikel lesen

28.03.

Nasdaq Stockholm AB: Listing of paid subscription unit of Bioextrax AB

With effect from April 02, 2024, the paid subscription unit in Bioextrax AB will be traded on First North Growth Market. Trading will continue until further notice. Instrument: Paid subscription...
► Artikel lesen

28.03.

Nasdaq Stockholm AB: Listing of unit rights of Bioextrax AB

With effect from April 02, 2024, the unit rights in Bioextrax AB will be traded on First North Growth Market. Trading will continue up until and including April 11, 2024. Instrument: Unit rights...
► Artikel lesen

25.03.

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024

Zeit	Aktuelle Nachrichten
18.04.	DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in the company's rights issue
16.04.	DIAMYD MEDICAL AB: Diamyd Medical announces preliminary outcome in the company's rights issue
12.04.	Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial	STOCKHOLM, April 12, 2024 /PRNewswire/ -- Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events... ► Artikel lesen
11.04.	DIAMYD MEDICAL AB: Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes
05.04.	DIAMYD MEDICAL AB: Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue

Zeit

Aktuelle Nachrichten

18.04.

DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in the company's rights issue

16.04.

DIAMYD MEDICAL AB: Diamyd Medical announces preliminary outcome in the company's rights issue

12.04.

Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial

STOCKHOLM, April 12, 2024 /PRNewswire/ -- Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events...
► Artikel lesen

11.04.

DIAMYD MEDICAL AB: Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes

05.04.

DIAMYD MEDICAL AB: Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue

Zeit	Aktuelle Nachrichten
25.03.	XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2024	The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2024ISIN NameCA30957Q1028 FARMERS... ► Artikel lesen
25.03.	XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024	Das Instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024 The instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY is traded ex capital adjustment on 25.03.2024Das... ► Artikel lesen
22.01.	XFRA K26: AUSSETZUNG/SUSPENSION	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILENIBLOCK EO -,01... ► Artikel lesen

Zeit

Aktuelle Nachrichten

25.03.

XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2024

The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2024ISIN NameCA30957Q1028 FARMERS...
► Artikel lesen

25.03.

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024

22.01.

XFRA K26: AUSSETZUNG/SUSPENSION

Zeit	Aktuelle Nachrichten
25.03.	XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024		Das Instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024 The instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY is traded ex capital adjustment on 25.03.2024Das... ► Artikel lesen
29.01.	XFRA RDT1: WIEDERAUFNAHME/RESUMPTION		FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen

Zeit

Aktuelle Nachrichten

25.03.

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024

29.01.

XFRA RDT1: WIEDERAUFNAHME/RESUMPTION

Zeit	Aktuelle Nachrichten
25.03.	XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024	Das Instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024 The instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY is traded ex capital adjustment on 25.03.2024Das... ► Artikel lesen
12.03.	XFRA P0X: WIEDERAUFNAHME/RESUMPTION	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen
11.03.	PHARNEXT: Pharnext takes full stock of its operating, strategic and financial situation	PARIS, France, March 11, 2024, 04:30 pm CET - Pharnext SA ( FR001400N1P4 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative... ► Artikel lesen
07.03.	XFRA P0X: AUSSETZUNG/SUSPENSION	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPHARNEXT EO -,20... ► Artikel lesen
28.02.	PHARNEXT: Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A	PARIS, France, February 28, 2024, 08:30 am CET - Pharnext SA ( FR001400N1P4 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen

Zeit

Aktuelle Nachrichten

25.03.

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024

12.03.

XFRA P0X: WIEDERAUFNAHME/RESUMPTION

11.03.

PHARNEXT: Pharnext takes full stock of its operating, strategic and financial situation

PARIS, France, March 11, 2024, 04:30 pm CET - Pharnext SA ( FR001400N1P4 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative...
► Artikel lesen

07.03.

XFRA P0X: AUSSETZUNG/SUSPENSION

28.02.

PHARNEXT: Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A

PARIS, France, February 28, 2024, 08:30 am CET - Pharnext SA ( FR001400N1P4 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Mi	XXL ASA - Annual Report 2023
Mi	XXL ASA - "Reset & Rethink" plan progressing well in a quarter with weak sales development, strengthened gross margin and strong cost control
18.04.	XXL ASA - New share capital registered
13.04.	XXL ASA - Disclosure of shareholding
13.04.	XXL ASA - Mandatory notification of trade

Zeit

Aktuelle Nachrichten

XXL ASA - Annual Report 2023

XXL ASA - "Reset & Rethink" plan progressing well in a quarter with weak sales development, strengthened gross margin and strong cost control

18.04.

XXL ASA - New share capital registered

13.04.

XXL ASA - Disclosure of shareholding

13.04.

XXL ASA - Mandatory notification of trade